Critical Analysis: MindWalk (HYFT) versus The Competition

MindWalk (NASDAQ:HYFT) is one of 450 public companies in the “Pharmaceutical Preparations” industry, but how does it compare to its peers? We will compare MindWalk to related companies based on the strength of its valuation, profitability, earnings, risk, institutional ownership, analyst recommendations and dividends.

Valuation and Earnings

This table compares MindWalk and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MindWalk	$17.59 million	-$21.69 million	-2.18
MindWalk Competitors	$432.51 million	-$67.33 million	-12.09

MindWalk’s peers have higher revenue, but lower earnings than MindWalk. MindWalk is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 39.2% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 6.8% of MindWalk shares are owned by insiders. Comparatively, 13.5% of shares of all “Pharmaceutical Preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares MindWalk and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MindWalk	-145.58%	-56.75%	-31.55%
MindWalk Competitors	-2,683.22%	-366.86%	-43.27%

Analyst Ratings

This is a breakdown of current recommendations for MindWalk and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1	1	0	0	1.50
MindWalk Competitors	4919	9984	15997	377	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 60.62%. Given MindWalk’s peers stronger consensus rating and higher possible upside, analysts plainly believe MindWalk has less favorable growth aspects than its peers.

Risk and Volatility

MindWalk has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, MindWalk’s peers have a beta of 5.82, indicating that their average stock price is 482% more volatile than the S&P 500.

Summary

MindWalk peers beat MindWalk on 8 of the 13 factors compared.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.